Comorbidity trajectories before and after the diagnosis of heart failure: A UK Biobank cohort study

Hugo MacGowan1, Oliver I Brown1, Michael Drozd1

  • 1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

PubMed

Insights

Heart failure (HF) often occurs in patients with existing conditions. Comorbidities accumulate over a decade before HF diagnosis, presenting opportunities for early intervention and prevention.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • Heart failure (HF) is a complex condition frequently accompanied by multiple comorbidities.
  • Understanding the sequence and timing of comorbidity accrual is crucial for developing preventative strategies.

Purpose of the Study:

  • To define the trajectory of comorbidity accrual in relation to heart failure diagnosis.
  • To identify potential windows for disease prevention in individuals at risk for HF.

Main Methods:

  • Utilized UK Biobank cohort data (n=9824) including primary and secondary care records.
  • Analyzed the time between HF diagnosis and 16 common comorbidities.
  • Conducted stratified analyses by sex and age at HF diagnosis.

Main Results:

  • Heart failure was the median fourth diagnosis chronologically.
  • Comorbidities accumulated for over a decade prior to HF, accelerating in the years preceding diagnosis.
  • Depression preceded HF by a median of 10.7 years; dementia by 0.7 years. All comorbidities appeared earlier in women.
  • Atrial fibrillation/flutter, hypertension, cancer, myocardial infarction, and osteoarthritis were common preceding conditions.

Conclusions:

  • Heart failure diagnosis typically occurs in individuals with established multiple long-term conditions.
  • A significant window exists for interventions to prevent HF, even in non-traditional contexts like cancer and osteoarthritis care.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
504
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K